Other biologics that act at the alarmin level are under study for asthma (e.g., anti-IL-33: etokimab, itepekimab; anti-IL-33R: astegolimab, melrilimab), but there are no clinical trial in CRS to date. The gene discussed is IL33; the disease is asthma.